Bextra Relaunch Plan Could Include Weekly Monitoring, Pfizer CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is focusing on finalizing Celebrex relabeling and safety study, but plans to turn attention to Bextra "once the dust settles," McKinnell says. Potential risk management plan for the COX-2 inhibitor could include weekly doctor's visits to monitor skin rash risk during first month of treatment.
You may also be interested in...
EMEA Gives Pfizer One Year To Provide Data For Bextra Reintroduction
European Medicines Agency concludes its review of the COX-2 class with formal recommendation to remove Bextra from the market and additional contraindications and warnings for class labeling. The agency will now turn its attention to the safety profile of “some conventional” NSAIDs.
EMEA Gives Pfizer One Year To Provide Data For Bextra Reintroduction
European Medicines Agency concludes its review of the COX-2 class with formal recommendation to remove Bextra from the market and additional contraindications and warnings for class labeling. The agency will now turn its attention to the safety profile of “some conventional” NSAIDs.
Pfizer Pulling Back “Traditional” DTC Ads, CEO McKinnell Says
The company is moving away from campaigns promoting brand awareness in favor of ads focusing on disease awareness and patient education, the Pfizer exec says. There is a “recognition” in the pharmaceutical industry that direct-to-consumer advertising needs to be reformed, McKinnell notes.